Researchers Coat Mitochondria with Metal-Organic Frameworks Without Disrupting Energy Production

Key points

• A collaboration between Politecnico di Milano and IRCCS Fondazione Istituto Neurologico Carlo Besta developed a method to coat mitochondria with Metal-Organic Frameworks (MOFs).
• The study, published in the Journal of the American Chemical Society on September 18, 2026, confirms that mitochondria continue to produce energy after being coated with these materials.
• The technique uses micromolar concentrations of MOFs to modify the mitochondrial surface without interfering with essential cellular functions.
• MOFs, recognized by the 2025 Nobel Prize in Chemistry, are customizable materials that could eventually facilitate mitochondrial transplantation or specific therapeutic tasks.
• The research was conducted through the BraiNs joint laboratory and funded by the Cal.Hub.Ria project under the Ministry of Health’s Health Operational Plan.

Background

This development follows recent advancements in understanding cellular structures and development. In September 2026, Stanford researchers published findings in Nature Neuroscience revealing that the human brain develops from two distinct progenitor lines, highlighting the complexity of cellular origins. While that study focused on embryonic development, the current research addresses the functional maintenance of existing cellular organelles. The broader field of nanomedicine is actively exploring ways to target specific cellular components, such as mitochondria, to treat diseases affecting energy-intensive tissues like the brain and muscles.

How outlets are covering it

SciTechDaily emphasizes the novelty of the coating technique, highlighting that it preserves mitochondrial bioenergetics and could pave the way for new treatments for malfunctioning mitochondria. The outlet focuses on the collaboration between medical genetics and materials engineering experts. In contrast, Bioengineer.org provides a broader context, noting that while nanomaterials like MOFs show promise in preclinical studies, significant barriers remain for clinical translation. Bioengineer.org points out that evidence is currently limited to animal models and conventional cultures, citing issues with safety, manufacturing, and long-term integration. Yahoo’s source appears to be a technical error page and provides no substantive content for comparison. The primary source is optimistic about future applications, while the secondary source offers a cautious perspective on the gap between preclinical feasibility and clinical efficacy.

Why it matters

Mitochondrial dysfunction is linked to various medical conditions, including rare diseases and disorders affecting the brain and muscles. Current treatment options are limited, making the ability to modify mitochondria without disrupting their function a significant potential breakthrough. If successful, this technology could enable more effective mitochondrial transplantation or targeted therapies, addressing a major gap in treating energy-related cellular disorders. The use of MOFs, which are highly customizable, offers a versatile platform for developing future medical interventions.

What to watch

Further experiments are required to determine if coated mitochondria perform better during transplantation than uncoated ones. Researchers will need to explore how different MOF properties can be tuned for specific therapeutic tasks. Additionally, the field must address unresolved obstacles in nanomedicine, including safety, regulatory approval, and scalable manufacturing, before these techniques can move from preclinical studies to human clinical trials.